Combination therapies that simultaneously modulate AMPK, ERK, PKC, and STAT3 pathways could synergistically inhibit ET-1-mediated fat cell activity, obesity, and obesity-related complications while improving metabolic health. The gene discussed is PRRT2; the disease is obesity due to melanocortin 4 receptor deficiency.